Ultragenyx announced plans to lay off 20% of employees and scrap a Wilson disease gene therapy program after setbacks in its recent development portfolio. The company said the workforce reduction marks a second time this year it has cut staff, following operational pressure after a quarter that included two FDA approvals alongside a major Angelman syndrome setback. The move highlights how quickly development failures can force capital reallocation, especially for small-to-mid biotech programs with high single-asset risk profiles. Investors will likely focus on what remains in Ultragenyx’s pipeline after the Wilson program discontinuation and how quickly the company can stabilize its development and commercial execution.